Francesco MASSONİ1, Lidia RİCCİ, Claudio SİMEONE, Serafino RİCCİ

Cardiac hypertrophy and heart failure: From the case to review of literature

In response to an increased workload due to physiological or pathological stimuli, the heart may undergo a process of growth with increased muscle mass called cardiac hypertrophy. It is a particular mechanism of long term compensation used by the heart to adapt permanently to a greater workload. Although, through its peculiar structural, molecular and metabolic characteristics, in early stage the hypertrophy allows to maintain an adequate cardiac function, after a variable period of time, the same characteristics promote the evolution to contractile dysfunction and heart failure. The latter represents an important cause of death and so the cardiac hypertrophy increases the cardiovascular morbidity and mortality. In this paper we report a rare case of extremely high degree of concentric cardiac hypertrophy, with a heart weight of 1050 g and longitudinal diameter of 16.5 cm, transverse diameter of 16 cm and antero-posterior diameter of 9 cm. The thickness of the left ventricle free wall was 4.2 cm, of the septum 4.3 cm and at the apex level 3.5 cm. These data, compared with those described in scientific literature, indicate the exceptional nature of our necropsy finding of a huge cardiac hypertrophy. The analysis of the pathogenetic mechanisms, which may determinate the fatal event in case of cardiac hypertrophy, shows that in the described case the death cause can be the onset of heart failure in presence of cardiomegaly.

___

1. Chugh SS, Kelly KL, Titus JL. Sudden cardiac death with apparently normal heart. Circulation 2000; 102: 649-654.

2. Gosse P, Dallocchio M. Left ventricular hypertrophy: epidemiological prognosis and associated critical factors. Eur Heart J 1993; 14: 16-21.

3. McMullen JR, Jennings GL. Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure. Clin Exp Pharmacol Physiol 2007; 34: 255-262.

4. Bella JN, Göring HHH. Genetic epidemiology of left ventricular hypertrophy. Am J Cardiovasc Dis 2012; 2: 267-278.

5. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001; 141: 334-341.

6. Katz AM. Maladaptive growth in the failing heart: the cardiomyopathy of overload. Cardiovasc Drugs Ther 2002; 16: 245-249.

7. McMurray JJ, Pfeffer MA. Heart failure. Lancet 2005; 365: 1877-1889.

8. Morimoto S, Sekiguchi M, Hiramitsu S, et al. Contribution of cardiac muscle cell disorganization to the clinical features of hypertrophic cardiomyopathy. Heart Vessels 2000; 15: 149-158.

9. Cummings PM, Le BH, Lopes MBS. Postmortem findings in morbidly obese individuals dying after gastric bypass procedures. Hum Pathol 2007; 38: 593-597.

10. Di Paolo M, Guidi B, Bugelli V, Naccarato GA. Sudden death of a sportsman. An unusual case of idiopathic form of pulmonary hypertension. Int J Legal Med 2012; 126: 52.

11. Giraldo RD, Guarin CV, Viloria VB. Sudden death: intramural coronary artery. Int J Legal Med 2012; 126: 196.

12. Schoen FJ, Mitchell RN. The Heart. In: Kumar V, Abbas AK, Fausto N, Aster J. Robbins and Cotran Pathologic Basis of Disease - 8th ed. Philadelphia: Saunders Elsevier; 2010, p. 529-587.

13. Hort W. Myocardial hypertrophy. Light microscopic findings on the myocardium. Blood supply. Ventricular dilatation and heart failure. Basic Res Cardiol 1977; 72: 203-208.

14. Dorn GW. The fuzzy logic of physiological cardiac hypertrophy. Hypertension 2007; 49: 962- 970.

15. Norton JM. Toward consistent definitions for preload and afterload. Adv Physiol Educ 2001; 25: 53-61.

16. Bernardo BC, Weeks KL, Pretorius L, McMullen JR. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther 2010; 128: 191-227.

17. Van Berlo JH, Maillet M, Molkentin JD. Signaling effectors underlying pathologic growth and remodeling of the heart. J Clin Invest 2013; 123: 37-45.

18. Brower GL, Gardner JD, Forman MF, et al. The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur J Cardiothorac Surg 2006; 30: 604-610.

19. Hudlicka O, Brown M, Egginton S. Angiogenesis in skeletal and cardiac muscle. Physiol Rev 1992; 72: 369-417.

20. Taegtmeyer H, Sen S, Vela D. Return to the fetal gene program: a suggested metabolic link to gene expression in the heart. Ann N Y Acad Sci 2010; 1188: 191-198.

21. Lopaschuk GD, Jaswal JS. Energy metabolic phenotype of the cardiomyocyte during development, differentiation, and postnatal maturation. J Cardiovasc Pharmacol 2010; 56: 130-140.

22. Abel ED, Doenst T. Mitochondrial adaptations to physiological versus pathological cardiac hypertrophy. Cardiovasc Res 2011; 90: 234-242.

23. Schunkert H. Obesity and target organ damage: the heart. Int J Obes 2002; 26: 15-20.

24. Harmancey R, Wilson CR, Taegtmayer H. Adaptation and maladaptation of the heart in obesity. Hypertension 2008; 52: 181-187.

25. Gardin JM, McClelland R, Kitzman D, et al. Mmode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure and mortality in an elderly cohort (The Cardiovascular Health Study). Am J Cardiol 2001; 87: 1051-1057.

26. Vatner SF. Reduced subendocardial myocardial perfusion as one mechanism for congestive heart failure. Am J Cardiol 1988; 62: 94-98.

27. Dorn GW. Myocardial angiogenesis: its absence makes the growing heart founder. Cell Metab 2007; 5: 326-327.

28. Levine B, Yuan J. Autophagy in cell death: an innocent convict? J Clin Invest 2005; 115: 2679- 2688.

29. Diwan A, Dorn GW. Decompensation of Cardiac Hypertrophy: Cellular Mechanisms and Novel Therapeutic Targets. Physiology 2007; 22: 56-64.

30. Narula J, Haider N, Virmani R, et al. Apoptosis in myocytes in endstage heart failure. N Engl J Med 1996; 335: 1182-1189.

31. Liu Y, Cigola E, Cheng W, et al. Myocyte nuclear mitotic division and programmed myocyte cell death characterize the cardiac myopathy induced by rapid ventricular pacing in dogs. Lab Invest 1995; 73: 771-787.

32. Thiedeman KU, Holubarsch CH, Medugorac I, Jacob R. Connective tissue content and myocardial stiffness in pressure overload hypertrophy: a combined study of morphologic, morphometric, biochemical, and mechanical parameters. Basic Res Cardiol 1983; 78: 140-155.

33. Scheuer J, Malhotra A, Hirsch C, Capasso J, Schaible TF. Physiologic cardiac hypertrophy corrects contractile protein abnormalities associated with pathologic hypertrophy in rats. J Clin Invest 1982; 70: 1300-1305.

34. Wankerl M, Schwartz K. Calcium transport proteins in nonfailing and failing heart: gene expression and function. J Mol Med 1995; 73: 487-496.

35. Neubauer S. The Failing Heart - An Engine Out of Fuel. N Engl J Med 2007; 356: 1140-1151.

36. Massoni F, Di Sabatino D, Ricci L, Onofri E, Ricci S. A rare case of myocardial infarction by myocardial bridging of circumflex artery. Clin Ter 2014; 165: 416-418.

37. Massoni F, Ricci S. Cardiac death by rupture of the right ventricular wall and hemopericardium. Cent Eur J Med 2014; 9: 45-48.

38. Massoni F, Ricci L, Di Sabatino D, Ricci S. Haemopericardium in hypercoagulability by diabetes and hypertension. Experim and Clin Card 2014; 20: 3100-3108.

39. Vitarelli A, Cortes Morichetti M, Capotosto L, et al. Utility of strain echocardiography at rest and after stress testing in arrhythmogenic right ventricular dysplasia. Am J Cardiol. 2013; 111: 1344-1350.